On August 10, 2023, Gregory Grunberg notified the board of directors (the ?Board?) of 89bio, Inc. (the ?Company?) of his intent to resign as a member of the Board and its committees, effective immediately. The size of the Board has been reduced to seven directors. Effective August 14, 2023, Dr. Grunberg is the Head of Life Sciences, North America at Temasek, an investment company. Dr. Grunberg?s resignation from the Board was not the result of any dispute or disagreement with the Company on any matter relating to the Company?s operations, policies or practices.
In connection with Dr. Grunberg?s resignation, the Board has appointed E. Morrey Atkinson III to serve as chair of the Nominating and Corporate Governance Committee and Kathleen D. LaPorte as a member of the Audit Committee.